Study Raises Questions About Weight-Loss Drugs

It says long-term reviews are needed to assess their benefits and risks

By Steven Reinberg
HealthDay Reporter

Related Encyclopedia • Abdominoplasty • Acidophilus • Ankle Sprains • Antioxidants More... Related Healthscout Videos Hungry Heart Power Out Fat Soy - Many Forms, Many Benefits Soy - Health Benefits Explained More... Related Drug Information • Klor-Con • Klor-Con ER More... Related News Articles • Childhood Diabetes Boosts Risk for Kidney Problems • Diabetes Group Backs Low-Carb Diets • Fish Oil May Help Prevent Alzheimer's • Study Spotlights 'Exercise-Friendly' Day-Care Centers More...

FRIDAY, Jan. 5 (HealthDay News) -- Millions of Americans take popular drugs to lose weight, but the long-term risks and benefits of these medications aren't known, two Canadian researchers contend.

Drs. Raj Padwal and Sumit Majumdar, of the University of Alberta, said long-term studies are needed to determine whether losing weight on drugs such as sibutramine (Meridia), orlistat (Xenical) and rimonabant (Acomplia) actually reduces the risks of heart attack, stroke and diabetes associated with being overweight or obese.

Text Continues Below

---

The physicians expressed their views in the Jan. 6 issue of The Lancet.

"These three medications will likely lower weight, modestly, but we need better studies," Padwal said. "The studies that are out there don't provide information on cardiovascular disease and cardiovascular deaths. The other problem is that they are not long-term and have high dropout rates. We really need to know what the net benefits of these medications are, and truly know whether we should be using them or not."

Padwal and Majumdar reviewed all the published studies on the risks and benefits of the drugs.

For example, Meridia is associated with improvement in some cardiovascular risk factors, but for some patients it raises blood pressure, Padwal said.

"If you are going to prescribe a weight-loss drug, the ultimate goal is not a cosmetic one. The ultimate goal is to get that person to be healthier and lower their risk of having cardiovascular problems," Padwal said. "If you are going to give a medication that raises the blood pressure, then you have to question, is the net benefit advantageous or am I putting this patient at increased risk."

Padwal noted that studies are now under way to determine the long-term benefits and risks of these drugs. But such studies take time, and drugs such as Merida and Xenical have been on the market for several years. "That's going to be eight to nine years of using the medication before we finally get more definitive evidence whether they are beneficial or not," he said.

Page:  1 | 2 | Next >>